BioVaxys Welcomes Former Sanofi Vaccines Executive to Board

BioVaxys Appoints Dr. James Tartaglia to Board of Directors

Vancouver, BC, October 8, 2025 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) is excited to announce the appointment of Dr. James Tartaglia, PhD, an esteemed executive with extensive experience in vaccine research and development, to its Board of Directors. This strategic move comes after the resignation of Director Anthony Dutton, who is stepping down to focus on personal commitments. BioVaxys wishes to express its gratitude for Dutton's dedicated service since his appointment in April 2022.

Dr. Tartaglia brings over 34 years of invaluable industry experience, having played a pivotal role in vaccine partnerships across various sectors including private enterprises, governmental initiatives, and international health organizations. Most recently, he served as the Global Head of Vaccine Development and Life Cycle Management at Sanofi, a prominent player in the pharmaceutical landscape, where he was key in managing a diverse portfolio of vaccination projects.

During his impressive tenure with Sanofi, Dr. Tartaglia steered a portfolio comprising 25 distinct vaccine projects, overseeing their development from initial phases through to life cycle management. His work spanned multiple vaccine types, including those for influenza, pediatric combinations, and rabies among others. In total, he has contributed to the licensure of 20 vaccines applicable to both human and veterinary health.

Before his pivotal role at Sanofi, Dr. Tartaglia was the Executive Director of Research at Virogenetics Corporation, where he was involved in advancing poxvirus vector technology for immunization purposes. His career also includes valuable research experiences with the New York State Department of Health and a postdoctoral fellowship at the Roche Institute of Molecular Biology. He holds a PhD in Microbiology and Immunology from Albany Medical College and a Bachelor of Science in Biology from Bucknell University.

An inventor on more than 20 patents related to recombinant vaccines, Dr. Tartaglia is also a prolific author, contributing over 130 publications in the realms of molecular virology and vaccine technology. Furthermore, he holds editorial responsibilities for various esteemed peer-reviewed journals.

Kenneth Kovan, President and COO of BioVaxys, expressed enthusiasm about Dr. Tartaglia's appointment, highlighting its significance in furthering their focus on DPX-based vaccine programs targeting critical areas of unmet medical needs. They aim to leverage collaboration opportunities with global vaccine companies to advance the DPX platform’s innovative capabilities.

BioVaxys Technology Corp. is committed to improving patient outcomes through cutting-edge biopharmaceutical developments, emphasizing immunotherapies that utilize their proprietary DPX immune-educating technology and HapTenix tumor cell construct platforms. Key projects in their pipeline include the DPX-based treatment for advanced cancers and therapies aimed at infectious diseases and food allergies.

With their shares listed on the Canadian Securities Exchange as well as the Frankfurt stock exchange and OTC markets in the United States, BioVaxys continues to position itself as a leader in the biopharmaceutical industry. For more details, please visit BioVaxys on their website or connect on social media platforms such as X and LinkedIn.

In conclusion, Dr. Tartaglia's extensive experience and contributions to vaccine development make him an invaluable addition to the BioVaxys board. The company looks forward to his insights as they aim to shape the future of vaccine therapy, tackling some of the most pressing health challenges today.